AbbVie and Eli Lilly are two rock-solid dividend plays, but only one is a buy right now.
Biogen's closely-watched Alzheimer's drug fails to move in the needle in two late-stage trials.
Tilray should consider a merger or possibly risk losing its premium valuation.
Novavax needs a deep-pocketed partner soon.
The drugmaker's Q4 earnings release was a big hit with investors.
The first stock you ever buy could be the most important. These three names won't disappoint.
BioScrip's fourth-quarter results and merger with Option Care Enterprises aren't sitting well with shareholders.
These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.
Investors are cheering HEXO's recent acquisition and strong second-quarter results today.
Aurora is hoping to attract a big-time partner to fund its global expansion.
Here's why investors should arguably never sell their shares of AbbVie, PepsiCo, or McDonald's.
Verastem's new oncology drug isn't setting the world on fire.
It has built one of the most diverse and far-reaching businesses in the legal marijuana space, but there are some missing pieces in its puzzle.
The biotech's limited cash runway is starting to weigh on its shares.
Teva's 2019 outlook sent investors packing last month.
Intercept's NASH data disappointed investors last month.
A new debt offering weighed on the biotech's shares last month.
The company's comeback story continued to gain momentum last month.
Novavax's latest clinical failure may prove to difficult to overcome.
These three small-cap stocks have outstanding growth potential.